New drug tested to calm electrical storms in Children's brains

NCT ID NCT04625101

Summary

This study tested whether an experimental drug called NBI-827104 could help children with a rare, severe form of epilepsy called epileptic encephalopathy with continuous spike-and-wave during sleep. Twenty-four children took the drug or a placebo daily for 13 weeks while researchers measured brain wave activity and asked caregivers and doctors about changes in symptoms. The goal was to see if the drug safely reduced the abnormal brain activity that causes seizures and developmental problems.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Neurocrine Clinical Site

    Orange, California, 92868, United States

  • Neurocrine Clinical Site

    Aurora, Colorado, 80045, United States

  • Neurocrine Clinical Site

    Washington D.C., District of Columbia, 20010, United States

  • Neurocrine Clinical Site

    Miami, Florida, 33155, United States

  • Neurocrine Clinical Site

    Rochester, Minnesota, 55905, United States

  • Neurocrine Clinical Site

    Durham, North Carolina, 27710, United States

  • Neurocrine Clinical Site

    Cleveland, Ohio, 44195, United States

  • Neurocrine Clinical Site

    Philadelphia, Pennsylvania, 19104, United States

  • Neurocrine Clinical Site

    Calgary, Alberta, T3B 6A8, Canada

  • Neurocrine Clinical Site

    Dianalund, 4293, Denmark

  • Neurocrine Clinical Site

    Barcelona, 08950, Spain

  • Neurocrine Clinical Site

    Madrid, 28034, Spain

  • Neurocrine Clinical Site

    Basel, 4031, Switzerland

  • Neurocrine Clinical Site

    Zurich, 8032, Switzerland

  • Neurocrine Clinical Site

    London, WC1N 3JH, United Kingdom

Conditions

Explore the condition pages connected to this study.